Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 9/20 | 0.71 |
| ▸ | HDAC6 | Q9UBN7 | 8/20 | 0.71 |
| ▸ | HDAC1 | Q13547 | 12/20 | 0.59 |
| ▸ | HDAC8 | Q9BY41 | 9/20 | 0.59 |
| ▸ | HDAC2 | Q92769 | 8/20 | 0.59 |
| ▸ | HDAC4 | P56524 | 5/20 | 0.59 |
| ▸ | HDAC10 | Q969S8 | 4/20 | 0.59 |
| ▸ | HDAC5 | Q9UQL6 | 4/20 | 0.59 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.53 |
| ▸ | MAOA | P21397 | 1/20 | 0.52 |
| ▸ | MAOB | P27338 | 1/20 | 0.52 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.50 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.50 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.50 |
| ▸ | MEF2D | Q14814 | 1/20 | 0.49 |
| ▸ | BCHE | P06276 | 1/20 | 0.49 |
| ▸ | ACHE | P22303 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23054865 | 0.88 | HDAC3 (0.75) | HDAC3HDAC6HDAC1HDAC8HDAC2 | |
| SCHEMBL12150981 | 0.83 | HDAC6 (1.00) | HDAC3HDAC6HDAC1HDAC8HDAC2 | |
| SCHEMBL13949775 | 0.82 | HDAC3 (0.65) | HDAC3HDAC6HDAC1HDAC8HDAC2 | |
| SCHEMBL24294041 | 0.82 | HDAC3 (0.69) | HDAC3HDAC6HDAC1HDAC8HDAC2 | |
| SCHEMBL17483934 | 0.80 | HDAC6 (0.65) | HDAC3HDAC6HDAC1HDAC8HDAC2 | |
| SCHEMBL8256427 | 0.78 | HDAC3 (0.68) | HDAC3HDAC6HDAC1HDAC8HDAC2 | |
| SCHEMBL22483000 | 0.77 | HDAC6 (0.55) | HDAC3HDAC6HDAC1HDAC8HDAC2 | |
| SCHEMBL12126798 | 0.77 | KDM4E (0.41) | HDAC3HDAC6MAOAMAOB | |
| SCHEMBL17483891 | 0.77 | HDAC1 (0.71) | HDAC3HDAC6HDAC1HDAC8HDAC2 | |
| SCHEMBL16806926 | 0.76 | HDAC6 (0.54) | HDAC3HDAC6HDAC1HDAC8HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110124701-A1 | USE OF HDAC INHIBITORS FOR THE TREATMENT OF LYMPHOMAS | NOVARTIS AG (CH) | 2011-05-26 | — | — | US | disclosed |
| US-20110118309-A1 | USE OF HDAC INHIBITORS FOR THE TREATMENT OF HODGKIN'S DISEASE | ATADJA PETER WISDOM | 2011-05-19 | — | — | US | disclosed |
| US-20110034531-A1 | USE OF HDAC INHIBITORS FOR THE TREATMENT OF MELANOMA | NOVARTIS AG (CH) | 2011-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118309-A1 | USE OF HDAC INHIBITORS FOR THE TREATMENT OF HODGKIN'S DISEASE | HDAC1, HDAC5, HDAC4 | HDAC3 8/4885HDAC6 10/4885HDAC1 1/4885 |
| US-20110124701-A1 | USE OF HDAC INHIBITORS FOR THE TREATMENT OF LYMPHOMAS | HDAC5, HDAC1, HDAC4 | HDAC3 10/4885HDAC6 11/4885HDAC1 2/4885 |
| US-20110034531-A1 | USE OF HDAC INHIBITORS FOR THE TREATMENT OF MELANOMA | HDAC5, HDAC1, HDAC9 | HDAC3 6/4885HDAC6 9/4885HDAC1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.